T JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR. Vaccine injection web site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity for the tumor in a murine glioma model. J Immunol. 2013; 190:61320. [PubMed: 23248259] 50. Ahuja SS. In vitro generation of functional human and murine dendritic cells. Approaches Mol Biol. 2001; 156:677. [PubMed: 11068751] 51. Smyth GK. Linear models and empirical bayes solutions for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3 Article3. 52. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics information. Cancer Discov. 2012; two:40104. [PubMed: 22588877]Author Manuscript Author Manuscript Author Manuscript Author ManuscriptSci Immunol. Author manuscript; offered in PMC 2017 October 26.Gabriely et al.Page53. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative evaluation of complicated cancer genomics and clinical profiles making use of the cBioPortal. Sci Signal. 2013; six:pl1. [PubMed: 23550210]Author Manuscript Author Manuscript Author Manuscript Author ManuscriptSci Immunol. Author manuscript; accessible in PMC 2017 October 26.Gabriely et al.PageAuthor Manuscript Author Manuscript Author Manuscript Author ManuscriptFigure 1. Therapeutic effect of anti-LAP in cancer models(A) B16 melanoma tumor volume over time in WT mice treated with either anti-LAP (TW7-28G11 clone) or IC antibodies (n=6 (anti-LAP) and n=7 (IC), in the last time point). Information are representative of at least three independent experiments.N-Boc-4-pentyne-1-amine In stock (B) Survival curves of WT mice with intracranial GL261 GBM treated with anti-LAP clone TW7-16B4 (n=17; data are combined from two independent experiments; log-rank test). Intracranial tumor growth measured by MRI (representative images) on days 15 and 22 (C) and by bioluminescence (BLI; representative photos) (D) and measured as relative BLI on days 13, 20 and 27 (E; n=6 (anti-LAP) and n=7 (IC), in the last time point). (F, G) Tumor volume of subcutaneous GL261 GBM implanted in WT mice and treated with anti-LAP clone TW7-28G11 (F, n=5) or anti-LAP clone TW7-16B4 (G, n=8). (H) Early therapeutic effect of anti-LAP on intracranial GL261 GBM. Variety of mice created solid tumors following anti-LAP therapy. (I, J) Orthotopic AOM/DSS induced CRC in WT mice treated with anti-LAP; tumor quantity (I) and representative images of CRC colons (J) are shown (n=9 (anti-LAP and IC) and n=5 (handle); one-way ANOVA).Pent-2-ynoic acid uses Information are representative of two independent experiments.PMID:24190482 (K ) Tumor volume of subcutaneous MC38 (K, n=5) and CT26 (L, n=5) CRC models in WT mice treated with anti-LAP. Information are representative of two independentSci Immunol. Author manuscript; readily available in PMC 2017 October 26.Gabriely et al.Pageexperiments. (M) CT26 tumor weight measured at day 20 (n=5; two-tailed t-test). (N) Percent survival in patients with fairly high or low mRNA expression of TGFB1 (LAP) according to z score. The “high” expression group was determined determined by pre-computed z score worth from gene expression (greater than 0.005-0.five) although the “low” group consisted in the remaining individuals in the dataset. Graphs and p values were downloaded from the Tumor Cancer Geno.
